March 31, 2022
Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.
March 24, 2022
Recommendations for monitoring patients on novel therapies used to manage lupus nephritis and making decisions to taper or stop treatment.
March 24, 2022
The rationale for treating lupus nephritis with novel therapies such as belimumab and voclosporin.
March 18, 2022
The rationale for using a newer monoclonal antibody therapy, anifrolumab, to manage patients with systemic lupus erythematosus.
March 18, 2022
Indications for belimumab, a monoclonal antibody, as therapy for patients with systemic lupus erythematosus.
March 11, 2022
Daniel J. Lovell, MD, MPH, explains the recent ACR guidelines updates regarding the treatment and management of juvenile idiopathic arthritis and the clinical significance of the changes.
March 10, 2022
Resources that can help educate patients with lupus about their diagnosis and encourage them to take a more proactive role in self-care.
March 10, 2022
Types of tests used to evaluate patients for signs of lupus or disease progression.
March 10, 2022
Roy Fleischmann, MD, discusses the usage of biosimilars in the United States and hypothesizes about what is in store for the future.
March 09, 2022
Roy Fleischmann, MD, examines the current state of biosimilars as it relates to rheumatologists in the United States.